BiotechTube
NovaGo Therapeutics

NovaGo Therapeutics

Basel, Switzerland· Est.
novagotherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

NovaGo Therapeutics is a private, clinical-stage biotech company pioneering a novel antibody-based approach to treat spinal cord injury (SCI). Its core technology involves a therapeutic antibody that blocks the Nogo-A receptor to overcome the natural inhibition of nerve regeneration in the central nervous system. Having demonstrated promising preclinical efficacy, the company is advancing towards initial human trials, with a Phase 1b study anticipated to start in 2024. Operating from the major European life sciences hub of Basel, NovaGo is targeting a high-unmet-need neurological condition with no approved disease-modifying therapies.

NeurologySpinal Cord Injury

Technology Platform

Human monoclonal antibody platform targeting the Nogo-A receptor pathway to overcome inhibition of nerve growth and regeneration in the central nervous system.

Opportunities

The global spinal cord injury market represents a major unmet need with no approved disease-modifying therapies, offering potential for premium pricing.
Success in SCI could enable platform expansion into other CNS disorders like stroke or multiple sclerosis where Nogo-A inhibition is relevant.
The company's Swiss location provides access to a strong life sciences ecosystem and potential grant funding.

Risk Factors

High clinical translation risk, as many regenerative approaches have failed to show efficacy in human spinal cord injury trials.
The company is pre-revenue and dependent on future fundraising in volatile markets.
Regulatory pathways for a first-in-class regenerative therapy are complex and endpoint definition is challenging.

Competitive Landscape

The competitive landscape includes other biotechs and academic groups exploring diverse approaches like cell therapies, neurostimulation devices, and other growth inhibitor targets (e.g., RGMa, CSPGs). While there are no approved pharmacologic regenerative therapies, NovaGo's focused antibody approach against a well-validated target (Nogo-A) positions it in a specific niche within this broad, high-stakes field.

More companies in Biologics / Biosimilars →More companies in Switzerland →